Harbour BioMed Announces Multi-Year Transgenic Platform Licensing Agreement with Celsius Therapeutics for Fully Human Monoclonal Antibody Drug Discovery SHANGHAI & ROTTERDAM, Netherlands & CAMBRIDGE, Mass. Harbour BioMed announced today that it has licensed its patented H2L2 fully human antibody discovery platform to Celsius Therapeutics, a newly launched company translating single-cell genomic insights into precision therapeutics. The license was issued through Harbour BioMed’s wholly owned subsidiary, Harbour Antibodies BV. Harbour BioMed’s H2L2 transgenic mouse platform enables biotechnology, pharmaceutical companies, and academia to accelerate new drug development by generating fully human monoclonal antibodies. Under the licensing agreement, Celsius Therapeutics has rights to use the H2L2 platform for multiple programs over a multi-year …
AbCellera and Harbour Antibodies Announce Technology Co-Offering Agreement for Next-Generation Fully-Human Antibody Discovery
AbCellera and Harbour Antibodies Announce Technology Co-Offering Agreement for Next-Generation Fully-Human Antibody Discovery Co-offering combines AbCellera’s microfluidic single-cell screening platform with Harbour’s H2L2 transgenic mouse technology to create an end-to-end solution for the discovery of fully-human lead therapeutic antibodies. VANCOUVER, British Columbia & ROTTERDAM, Netherlands & CAMBRIDGE, Mass AbCellera and Harbour Antibodies, a Harbour BioMed subsidiary, announced today that they have entered into an agreement to combine AbCellera’s single-cell antibody discovery capabilities with Harbour’s H2L2 transgenic mouse platform, establishing an industry-leading discovery solution that enables the generation of large panels of fully-human therapeutic antibodies with unmatched speed, quality and efficiency. The combined offering eliminates the need for antibody humanization, and …
Harbour BioMed will give a presentation at PEGS-Boston Conference 2018
April 30th – May 4th, 2018 Seaport World Trade Center Boston, MA Please stop by our Booth 601! Oncology Stream Luncheon Presentation #1 Time: 12:50 PM, April 30th, 2018 Title: In Vivo Platform for Generation Human “Heavy Chain Only” Antibodies for Drug Discovery Presenter: Frank Grosveld, Ph.D., Professor of Cell Biology, Erasmus MC, and Founder of Harbour Antibodies BV Profile: Dr. Frank Grosveld founded Harbour Antibodies in 2006 at Erasmus MC, Rotterdam, the Netherlands. He and his team were responsible for the development of two strains of transgenic mice for generating human therapeutic antibodies: (1) H2L2 – mice that generate antibodies comprised of two heavy chains and two light chains …
Harbour BioMed Announces Multi-Year Transgenic Platform Licensing Agreement with Innovent Biologics, Inc. for Fully Human Monoclonal Antibody Drug Discovery
October 12th, 2017 SHANGHAI, China, ROTTERDAM, The Netherlands and CAMBRIDGE, MA Harbour BioMed announced today that it has licensed its patented H2L2 transgenic mouse platform for generating fully human therapeutic monoclonal antibodies, to Innovent Biologics, Inc., a leading biopharmaceutical company in China. The license was issued through Harbour BioMed’s wholly owned subsidiary, Harbour Antibodies BV. Harbour BioMed’s transgenic H2L2 platform enables biotechnology and pharmaceutical companies and academic research labs to accelerate new drug development by generating fully human antibodies. Under the licensing agreement, Innovent Biologics has rights to use the H2L2 platform for multiple projects over a multi-year licensing term. Harbour will receive an upfront payment, fees and milestones as …